The Chain: Protein Engineering Podcast

T cell and immune cell engagement is gaining traction, but what makes it different from other therapies? Patrick Baeuerle, Ph.D., chief scientific advisor at Cullinan Therapeutics, and Jeffrey Miller, M.D., deputy director of Masonic Cancer Center, join The Chain to discuss the advantages, similarities, and differences of T cell and immune cell engagers, and how they compare to other modalities such as CAR T cells. Hosted by Laszlo Radvanyi, Ph.D., their conversation covers engineering recogn...

During last year’s PEGS Europe, industry experts gathered on a panel to discuss the future of biologic therapeutics. The panel kicked off with a presentation on 50 years of monoclonals, from hybridomas to next-gen antibody therapeutics, followed by a conversation featuring Paul Carter, Ph.D., Genentech Fellow of Antibody Engineering, G. Jonah Rainey, Ph.D., associate vice president of Eli Lilly and Company, and Janine Schuurman, Ph.D., biotech consultant at Lust for Life Science B.V. Moderate...

How has immunotherapy evolved in the last decade? In this episode of The Chain, Laszlo Radvanyi, professor of immunology at the University of Toronto, discusses his years-long research on cancer immunotherapy, including his time at MD Anderson, with host Rakesh Dixit. He shares his thoughts on agonist antibodies, the true breakthroughs that are moving the needle for patients, reducing the CD-28 pathway so that it doesn’t produce cytokine toxins, and what is the next frontier in immunotherapy....

December 13, 2025 | What is next for immunogenicity? In this episode of The Chain, Vibha Jawa, chief scientific officer at EpiVax, provides her thoughts and insights on BiTE molecules, pegylated molecules, and other biologic molecules and their impact on cancer treatment and research with host Rakesh Dixit. Jawa shares the most rewarding project she’s worked on and what therapeutic modality she sees being picked up in the next decade, as well as advice for the next generation of scientists, s...

November 11, 2025 | What is the next modality to focus on in the next 10 years? For Bahija Jallal, CEO of Immunocore, it would be T-cell engagers. In this episode of The Chain, host Rakesh Dixit speaks with Jallal on the potential advantages of bispecific T-cell engager therapy versus T-cell receptor therapy, biggest anticipated changes in drug discovery and development in the next 10 years, and how AI is going to impact the next generation of scientists. Plus, Jallal shares her experiences a...